How big is the Immunotherapy Drugs Market?

The Immunotherapy Drugs Market size is expected to reach USD 118 billion in 2024 and grow at a CAGR of 8.40% to reach USD 192 billion by 2029. Read More

What is the current Immunotherapy Drugs Market size?

In 2024, the Immunotherapy Drugs Market size is expected to reach USD 118 billion. Read More

Who are the key players in Immunotherapy Drugs Market?

GlaxoSmithKline plc, Amgen Inc., Novartis AG, AbbVie Inc. and F. Hoffmann-La Roche AG are the major companies operating in the Immunotherapy Drugs Market. Read More

Which is the fastest growing region in Immunotherapy Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Immunotherapy Drugs Market?

In 2024, the North America accounts for the largest market share in Immunotherapy Drugs Market. Read More

What years does this Immunotherapy Drugs Market cover, and what was the market size in 2023?

In 2023, the Immunotherapy Drugs Market size was estimated at USD 108.09 billion. The report covers the Immunotherapy Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Immunotherapy Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Immunotherapy Drugs Market Share

Statistics for the 2023 & 2024 Immunotherapy Drugs market share, created by Mordor Intelligence™ Industry Reports. Immunotherapy Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Immunotherapy Drugs Industry

The immunotherapy drugs market is moderately fragmented and consists of several major players. In terms of market share, few of the major players currently dominate the market. The market players are focusing on new product launches, R&D, and expansions to gain a competitive advantage. Some of the market's major players include AbbVie Inc., Amgen Inc., AstraZeneca, GlaxoSmithKline PLC, Novartis AG, and F. Hoffmann-La Roche AG.